NASDAQ: OPK · Life Sciences · 5 alerts · CIK 944809
Share price
$1.62Close, Nov 16
Market cap
$1.2B
Shares outstanding
742.51MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Opko Health, Inc. filings on SEC EDGAR ↗
Opko Health Director John A. Paganelli Sells $16.7K of Stock
John A. Paganelli, Director, sold 9,175 shares of Opko Health, Inc. at $1.82 a share, worth $16.7K in total on Nov 5, 2026. Shares held after the trade: 0 (-100.0%).
OPKO Health reported total assets of $1.88 billion as of September 30, 2026, with a significant shift of $248 million into current assets held for sale. The company maintains a cash position of $390.2 million while managing $370.2 million in senior secured royalty financing and $92.5 million in convertible notes.
OPKO Health reported its third quarter 2026 financial results, highlighting a pending $722 million sale of its BioReference diagnostic operations to Labcorp. The company also expanded its financing with HealthCare Royalty by $125 million and advanced several clinical programs, including dosing the first participant in a Phase 1/2a trial for acromegaly.
Opko Health Divestiture to Laboratory Corporation of America Holdings for $722M
OPKO Health and its subsidiary BioReference Health entered into a definitive agreement to sell certain assets of their clinical and anatomic pathology laboratory testing business to Labcorp for $722 million in cash. The deal includes clinical and women’s health testing, urology, and the proprietary 4Kscore prostate cancer test, with OPKO eligible for up to an additional $150 million in milestone payments over ten years based on 4Kscore revenue. The transaction is subject to HSR Clearance and customary closing conditions, with a target completion date by April 14, 2027.
Opko Health $121M Debt Financing with U.S. Bank Trust Company, National Association
OPKO Health announced that its 3.75% Convertible Senior Notes due 2029 have become convertible by holders through December 31, 2026, after the stock price exceeded 130% of the conversion price for a specified period. The company has elected to settle these conversion obligations in shares of common stock rather than cash. Approximately $121 million in principal amount of these notes remains outstanding.